Trial record 1 of 1 for:
NCT02389894
Neuroprotection in Patients Undergoing Aortic Valve Replacement
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02389894 |
|
Recruitment Status :
Completed
First Posted : March 17, 2015
Results First Posted : April 29, 2019
Last Update Posted : April 29, 2019
|
Sponsor:
Icahn School of Medicine at Mount Sinai
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Annetine Gelijns, Icahn School of Medicine at Mount Sinai
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
To evaluate the efficacy and safety of embolic protection devices to reduce ischemic brain injury in patients undergoing surgical aortic valve replacement (AVR).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Aortic Stenosis Brain Infarction Cerebrovascular Accident Stroke | Device: Embol-X Embolic Protection Device Device: CardioGard Cannula | Not Applicable |
This is a multicenter randomized trial in which patients diagnosed with calcific aortic stenosis (AS) with planned AVR will be randomized to 1) the treatment arm of the Edwards Life Science filter and cannula or the filter as a stand alone with any cannula or 2) to the treatment arm of the CardioGard cannula versus 3) standard care in a 1:1:1 ratio.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 383 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Outcomes Assessor) |
| Primary Purpose: | Prevention |
| Official Title: | Neuroprotection In Patients Undergoing Aortic Valve Replacement |
| Study Start Date : | March 2015 |
| Actual Primary Completion Date : | January 2017 |
| Actual Study Completion Date : | January 2017 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Supravalvular aortic stenosis
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Embol-X Embolic Protection Device
The surgeon may use either the EMBOL-X® Access Device/Aortic Cannula or a standard cannula with the EMBOL-X® filter deployed through a separate introducer sheath.
|
Device: Embol-X Embolic Protection Device
per the manufacturer's instructions for use (IFU).
Other Name: Edwards Embol-X embolic protection device |
|
Active Comparator: CardioGard Cannula
The Cardiogard embolic protection device is a curved tip 24-French aortic perfusion cannula.
|
Device: CardioGard Cannula
CardioGard Cannula, per the manufacturer's instructions for use (IFU).
Other Name: CardioGard Emboli Protection Cannula |
|
No Intervention: Standard Cannula
Patients in this arm will receive the standard of care surgical procedure using a cannula of the surgeon's choosing.
|
Primary Outcome Measures :
- Percentage of Participants With Freedom From Clinical or Radiographic Central Nervous System (CNS) Infarction [ Time Frame: up to 10 days post procedure ]freedom from CNS infarction, defined as brain, spinal cord, or retinal cell death attributable to ischemia based on neuropathological, neuroimaging, or clinical evidence of permanent injury based on symptoms persisting > 24 hours, with overt symptoms or no known symptoms. All patients will be assessed by 1.5 T (3.0 T is acceptable if 1.5 T not available) Diffusion-weighted imaging (DWI) at 7 (± 3) days post procedure for presence of brain lesions and to measure the number and volume of any present lesions.
Secondary Outcome Measures :
- Number of Participants With a Composite Endpoint of Mortality, Clinical Stroke, and Acute Kidney Injury [ Time Frame: up to 30 days ]The number of patients who have had a clinical ischemic stroke, acute kidney injury (AKI), or death within 30 days of surgery.
- Number of Patients With Clinically Apparent Stroke at 7 Days [ Time Frame: at 7 days ]The number of patients who experience a clinically apparent stroke by 7 days post-op
- Presence of Radiographic Infarcts [ Time Frame: up to 10 days ]The proportion of patients with radiographic infarcts on day 7 (+/-3 days) MRI. Presences of radiographic infarcts were measured using diffusion-weighted 1.5 or 3T MRI scanners
- Total Infarct Volume [ Time Frame: Day 7 ]Total infarct volume measured on day 7 dwMRI.
- Decline in Overall Neurocognition [ Time Frame: baseline and 90 days ]Decline in neurocognitive function at 90 days as compared to baseline. Decline defined as the number of patients whose Z score (computed relative to the study population at baseline, adjusting for age, education and sex) at day 90 had decreased by 0.5 SD relative to the baseline score.
- Decline in Neurocognitive Function in the Verbal Memory Domain at 90 Days [ Time Frame: baseline and 90 days ]Decline in neurocognitive function in the verbal memory domain at 90 days as compared to baseline. Decline defined as the number of patients whose Z score (computed relative to the study population at baseline, adjusting for age, education and sex) at day 90 had decreased by 0.5 SD relative to the baseline score.
- Decline in Neurocognitive Function in the Visual Memory Domain at 90 Days [ Time Frame: baseline and 90 days ]Decline in neurocognitive function in the visual memory domain at 90 days as compared to baseline. Decline defined as the number of patients whose Z score (computed relative to the study population at baseline, adjusting for age, education and sex) at day 90 had decreased by 0.5 SD relative to the baseline score.
- Decline in Neurocognitive Function in the Executive Function Domain at 90 Day [ Time Frame: baseline and 90 days ]Decline in neurocognitive function in the executive function domain at 90 days as compared to baseline. Decline defined as the number of patients whose Z score (computed relative to the study population at baseline, adjusting for age, education and sex) at day 90 had decreased by 0.5 SD relative to the baseline score.
- Decline in Neurocognitive Function in the Visuospatial/Constructional Praxis Domain at 90 Days [ Time Frame: baseline and 90 days ]Decline in neurocognitive function in the visuospatial/constructional praxis domain at 90 days as compared to baseline. Decline defined as the number of patients whose Z score (computed relative to the study population at baseline, adjusting for age, education and sex) at day 90 had decreased by 0.5 SD relative to the baseline score.
- Decline in Neurocognitive Function in the Auditory-Verbal Simple Attention Domain at 90 Days [ Time Frame: baseline and 90 days ]Decline in neurocognitive function in the Auditory-Verbal Simple attention domain at 90 days as compared to baseline. Decline defined as the number of patients whose Z score (computed relative to the study population at baseline, adjusting for age, education and sex) at day 90 had decreased by 0.5 SD relative to the baseline score.
- Decline in Neurocognitive Function in the Visuomotor/Information Processing Speed Domain at 90 Days [ Time Frame: baseline and 90 days ]Decline in neurocognitive function in the Visuomotor/Information Processing Speed domain at 90 days as compared to baseline. Decline defined as the number of patients whose Z score (computed relative to the study population at baseline, adjusting for age, education and sex) at day 90 had decreased by 0.5 SD relative to the baseline score.
- Modified Rankin Scale >2 at 90 Days [ Time Frame: 90 days ]
The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms.
- - No significant disability. Able to carry out all usual activities, despite some symptoms.
- - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
- - Moderate disability. Requires some help, but able to walk unassisted.
- - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
- - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
- - Dead.
- Barthel Index <= 80 [ Time Frame: 90 days ]An overall score has full range from 0 to 100, with higher scores indicating greater independence.
- Number of Participants With Confusion Assessment Method (CAM) Delirium Assessment at 7 Days [ Time Frame: 7 days ]
- Mortality by 90 Days [ Time Frame: up to 90 days ]Incidence of all-cause mortality
- Length of Stay for Index Hospitalization [ Time Frame: up to 90 days ]
- Hospital Readmissions [ Time Frame: up to 90 days ]Rate of hospital readmissions
- Quality of Life - Physical Health Composite [ Time Frame: at 90 days ]Quality of Life - Physical Health Composite Assessed by Short Form-12 (SF-12). Score ranking from 0 (worst health) to 100 (best health) calculated as the weighted sum of the questions. health scores then transformed into a t-score on the assumption that each question carries equal weight and were standardized to have mean of 50 and standard deviation of 10.
- Quality of Life - Mental Health Composite [ Time Frame: at 90 days ]Quality of life - Mental health composite Assessed by Short Form-12 (SF-12). Score ranking from 0 (worst health) to 100 (best health) calculated as the weighted sum of the questions. health scores then transformed into a t-score on the assumption that each question carries equal weight and were standardized to have mean of 50 and standard deviation of 10.
- Number of Participants With Emboli Captured [ Time Frame: day 1 ]Assessed by the presence of any debris captured in filter of embolic protection device
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 60 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age ≥ 60 years
- Planned and scheduled surgical aortic valve replacement via a full or minimal-access sternotomy (using central aortic perfusion cannulae) for calcific aortic stenosis with a legally marketed valve
- No evidence of neurological impairment as defined by a NIHSS ≤1 and modified Rankin scale (mRS) ≤ 2 within 7 days prior to randomization
- Ability to provide informed consent and comply with the protocol
Exclusion Criteria:
- Contraindication to legally marketed embolic protection devices (e.g. aneurysm of the ascending aorta, aortic trauma, porcelain aorta, known sensitivity to heparin)
- History of clinical stroke within 3 months prior to randomization
- Cardiac catheterization within 3 days of the planned aortic valve replacement
- Cerebral and or aortic arch arteriography or interventions within 3 days of the planned aortic valve replacement
- Active endocarditis at time of randomization
- Anticipated inability to tolerate or contraindication for MRI (e.g., known intolerance of MRI, permanent pacemaker at baseline or expected implantation of a permanent pacemaker)
- Any other concomitant aortic procedure such as root replacement
- Concomitant surgical procedures other than CABG, mitral annuloplasty, left atrial appendage (LAA) excision or exclusion, atrial septal defect (ASD) closure or patent foramen ovale (PFO) closure
- Clinical signs of cardiogenic shock or treatment with IV inotropic therapy prior to randomization
- Concurrent participation in an interventional (drug or device) trial
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02389894
Locations
Show 18 study locations
Sponsors and Collaborators
Icahn School of Medicine at Mount Sinai
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
| Principal Investigator: | Annetine C Gelijns, PhD | Icahn School of Medicine at Mount Sinai | |
| Study Chair: | Richard Weisel, MD | Toronto General Hospital |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Annetine Gelijns, Chair, Department of Population Health Science & Policy, Edmond A. Guggenheim Professor of Health Policy Co-Director, InCHOIR, Icahn School of Medicine at Mount Sinai |
| ClinicalTrials.gov Identifier: | NCT02389894 |
| Other Study ID Numbers: |
GCO 08-1078-0009 2U01HL088942-07 ( U.S. NIH Grant/Contract ) |
| First Posted: | March 17, 2015 Key Record Dates |
| Results First Posted: | April 29, 2019 |
| Last Update Posted: | April 29, 2019 |
| Last Verified: | April 2019 |
Keywords provided by Annetine Gelijns, Icahn School of Medicine at Mount Sinai:
|
Embolic Protection Device Stroke Brain Infarction atheroma Aortic Valve Replacement |
Additional relevant MeSH terms:
|
Stroke Brain Infarction Aortic Valve Stenosis Infarction Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases |
Cardiovascular Diseases Ischemia Pathologic Processes Necrosis Aortic Valve Disease Heart Valve Diseases Heart Diseases Ventricular Outflow Obstruction Brain Ischemia |